Supplementary Data

Covariate[a]	Hazard ratio[b]	95% CI	p-value
ATV/r treatment discontinuation			
Gender: females vs. males	1.52	1.25, 1.82	<0.001
Baseline detectable viremia,[c] yes vs. no	1.29	1.04, 1.61	0.022
Germany vs. France	1.12	0.91, 1.40	0.288
Sweden vs. France	1.63	1.27, 2.08	<0.001
Protease inhibitors vs. no protease inhibitors[c]	4.92	3.77, 6.42	<0.001
NRT inhibitors vs. no NRT inhibitors[c]	1.56	1.14, 2.13	0.006
Non-NRT inhibitors vs. no non-NRT inhibitors[c]	3.23	2.27, 4.58	<0.001
Other antiretrovirals vs. no other antiretrovirals[c]	31.34	7.62, 128.86	<0.001
Baseline detectable viremia[c] × protease inhibitors	0.60	0.42, 0.85	0.004
Baseline detectable viremia[c] × other antivirals	0.05	0.01, 0.25	<0.001
Protease inhibitors × non-NRT inhibitors	0.38	0.22, 0.64	<0.001
Non-NRT inhibitors × Germany	1.44	0.86, 2.40	0.163
Non-NRT inhibitors × Sweden	0.45	0.23, 0.90	0.024
Time to virologic failure			
Gender: females vs. males	1.04	0.83, 1.30	.743
Baseline detectable viremia,[c] yes vs. no	3.74	2.91, 4.81	<0.001
Germany vs. France	1.04	0.82, 1.32	0.745
Sweden vs. France	1.93	1.45, 2.56	<0.001
Protease inhibitors vs. no protease inhibitors[c]	2.73	1.84, 4.04	<0.001
NRT inhibitors vs. no NRT inhibitors[c]	2.12	1.36, 3.33	0.001
Non-NRT inhibitors vs. no non-NRT inhibitors[c]	2.17	1.34, 3.51	0.002
Other antivirals relative to no other antivirals	0.00	0.00, 1.7E165	0.967
Baseline detectable viremia[c] × protease inhibitors	0.60	0.38, 0.95	0.031
Baseline detectable viremia[c] × other antivirals	7807.32	0.00, 5.34E172	0.964
Protease inhibitors × non-NRT inhibitors	0.96	0.47, 1.97	0.914
Non-NRT inhibitors × Germany	0.59	0.27, 1.30	0.191
Non-NRT inhibitors × Sweden	0.37	0.15, 0.91	0.031

[a]Number (%) of patients used in the model, 1262 (98%).

[b]Covariate adjusted hazard ratio of time to discontinuation or virologic failure. Defined as ≥500 copies/ml. Only significant variables (p-value <0.05) were included with the exception of gender and detectable viremia, which were known to be significant and so have been forced into the model. The model was rerun with only those variables kept in the final model using backward elimination, thus maximizing the number of patients used in the analysis.

[c]Use as the last concomitant therapy (that is the last drug class recorded in combination with ATV/r before discontinuation).

CI, confidence interval; NRT, nucleoside reverse transcriptase.